Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
An announcement from MaxCyte ( (MXCT) ) is now available.
MaxCyte, Inc. has announced the acquisition of SeQure Dx, a leader in gene editing safety analytics, to enhance its cell engineering offerings. This acquisition aims to integrate SeQure Dx’s comprehensive assessment services into MaxCyte’s portfolio, allowing the company to better support cell and gene therapy developers by providing precise editing confirmation and risk assessment tools. This strategic move is expected to strengthen MaxCyte’s market position and accelerate its growth in the cell and gene therapy industry, with potential benefits for stakeholders through revenue growth and improved operational efficiencies.
More about MaxCyte
MaxCyte, Inc. is a leading company focused on cell engineering solutions that advance the discovery, development, and commercialization of next-generation cell therapeutics. The company specializes in providing cell therapy solutions and tools that support the development of cell-based medicines. MaxCyte’s ExPERT™ platform, based on Flow Electroporation® technology, serves the cell therapy market through its various products and services.
YTD Price Performance: 15.74%
Average Trading Volume: 63,632
Technical Sentiment Consensus Rating: Sell
Current Market Cap: £396.5M
See more insights into MXCT stock on TipRanks’ Stock Analysis page.
